Zevra Therapeutics logo

Zevra TherapeuticsNASDAQ: ZVRA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

16 April 2015

Next earnings report:

28 March 2025

Last dividends:

N/A

Next dividends:

N/A
$479.85 M
-1%vs. 3y high
65%vs. sector
-vs. 3y high
-vs. sector
-47%vs. 3y high
88%vs. sector
-13%vs. 3y high
86%vs. sector

Price

after hours | Thu, 21 Nov 2024 00:26:58 GMT
$8.99$0.00(0.00%)

Dividend

No data over the past 3 years
$3.69 M$8.52 M
$3.69 M-$33.23 M

Analysts recommendations

Institutional Ownership

ZVRA Latest News

Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript
seekingalpha.com13 November 2024 Sentiment: NEUTRAL

Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Nichol Ochsner - VP, IR & Corporate Communications Neil McFarlane - President & CEO LaDuane Clifton - CFO Joshua Schafer - Chief Commercial Officer & EVP, Business Development Conference Call Participants Jason Butler - JMP Securities Louise Chen - Cantor Fitzgerald Samantha Corwin - William Blair Eddie Hickman - Guggenheim Securities Sumant Kulkarni - Canaccord Genuity Oren Livnat - H.C. Wainwright Operator Good afternoon, and thank you for joining Zevra Therapeutics Third Quarter Financial Results and Corporate Update Conference Call.

Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates
zacks.com12 November 2024 Sentiment: NEGATIVE

Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.40 per share a year ago.

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting
globenewswire.com11 November 2024 Sentiment: POSITIVE

Data show that the NPCCSS swallow score reflects the patient's level of dysfunction Study indicates that a change in score reflects actual improvement or worsening in a patient's swallowing function CELEBRATION, Fla., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that Elizabeth Berry-Kravis, M.D.

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13
globenewswire.com06 November 2024 Sentiment: POSITIVE

CELEBRATION, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will participate in a fireside chat at the Guggenheim Securities Healthcare Innovation Conference Virtual on Wednesday, Nov. 13, 2024, at 4 p.m. ET. Additionally, management will be available for one-on-one meetings with registered attendees.

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
globenewswire.com10 October 2024 Sentiment: POSITIVE

CELEBRATION, Fla., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will participate in a Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC on Thursday, October 17, 2024 at 2 p.m. ET.

Zevra Stock Surges Close to 70% in 3 Months: Here's Why
zacks.com04 October 2024 Sentiment: POSITIVE

The FDA approval for ZVRA's Miplyffa (arimoclomol) capsules in September for treating Niemann-Pick disease type C drives the stock.

Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last?
zacks.com25 September 2024 Sentiment: NEUTRAL

Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024
globenewswire.com24 September 2024 Sentiment: POSITIVE

KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase 3 study CELEBRATION, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a commercial-stage rare disease therapeutics company, today announced that Rene Braeckman, Ph.D.

Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C
globenewswire.com20 September 2024 Sentiment: POSITIVE

MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disease

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
globenewswire.com06 September 2024 Sentiment: POSITIVE

New clinical efficacy and safety data for arimoclomol as a possible treatment for Niemann-Pick disease type C, including from long-term and real-world settings, demonstrate clinically meaningful reduction in disease progression

  • 1(current)

What type of business is Zevra Therapeutics?

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

What sector is Zevra Therapeutics in?

Zevra Therapeutics is in the Healthcare sector

What industry is Zevra Therapeutics in?

Zevra Therapeutics is in the Biotechnology industry

What country is Zevra Therapeutics from?

Zevra Therapeutics is headquartered in United States

When did Zevra Therapeutics go public?

Zevra Therapeutics initial public offering (IPO) was on 16 April 2015

What is Zevra Therapeutics website?

https://zevra.com

Is Zevra Therapeutics in the S&P 500?

No, Zevra Therapeutics is not included in the S&P 500 index

Is Zevra Therapeutics in the NASDAQ 100?

No, Zevra Therapeutics is not included in the NASDAQ 100 index

Is Zevra Therapeutics in the Dow Jones?

No, Zevra Therapeutics is not included in the Dow Jones index

When was Zevra Therapeutics the previous earnings report?

No data

When does Zevra Therapeutics earnings report?

The next expected earnings date for Zevra Therapeutics is 28 March 2025